Clinical Trial Update: Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of pegylated interferon lambda in HBeAg-positive hepatitis B patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated Interferon Lambda (pegylated interferon lambda-1a)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis B Virus | Phase 2 | Status: COMPLETED